Pelger-Huët anomaly is an inherited condition characterized by hyposegmentation of the neutrophil nucleus and excessive chromatin clumping. Acquired Pelger-Huët, also known as pseudo-Pelger-Huët, has been described in several clinical conditions including transplant recipients who received immunosuppressive drugs. The incidence of pseudo-Pelger-Huët in kidney transplant patients, characterized as neutrophil dysplasia, was observed in 9 of 170 patients (5.3%) at the São Francisco Hospital de Assis, Belo Horizonte, Brazil. Awareness of possible circulating neutrophil alterations in transplant patients is important for laboratory professionals who should report these findings of cell changes. It should be highlighted that the poor segmentation and the chromatin hypercondensation observed initially in pseudo-Pelger-Huët patients can be suggestive of early-stage neutrophils. Only a combination of laboratory and clinical data will facilitate a better understanding of this anomaly and its correct follow-up and management.

Keywords:
Kidney-transplanted patients, Neutrophils, Pseudo-Pelger-Huët
1.
Sotelo-Cruz N, Gonzalez-Olivas A, Covarrubias-Espinoza G, Lira Garces JL, Valencia-Mayoral P: The Pelger-Huet anomaly. A clinical and ultrastructural study of a family from northeastern Mexico. Bol Med Hosp Infant Mex 1991;48:261–266.
2.
Gondo H, Okamura C, Osaki K, Asano Y, Okamura T: Acquired Pelger-Hüet anomaly in association with concomitant tacrolimus and fluconazole therapy following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;26:1255–1277.
3.
Tomonaga M: Nuclear abnormalities in Pelger-Huet; progress in blood cell morphology. Rinsho Byori 2005;1:54–60.
4.
Banerjee R, Halil O, Brain BJ, Cummins D, Banner NR: Neutrophil dysplasia caused by mycophenolate mofetil. Transplantation 2000;70:1608–1610.
5.
Daliphard S, Accard F, Delattre C, Toupance D, Guyot C, Méchinaud F, Chassaing A, Hourmant M, Rousset P, Poltron G: Reversible abnormal chromatin clumping in granulocytes from six transplant patients treated with mycophenolate mofetil: a rare adverse effect mimicking abnormal chromatin clumping syndrome. Br J Haematol 2002;116:726–727.
6.
Masat T, Feliu E, Tassies D, Rovira M, Granena A, Rozman C: Pseudo Pelger-Hüet anomaly after bone marrow transplantation. Hematol Pathol 1991;5:89–91.
7.
Kennedy GA, Kay TD, Johnson DW, Hawley CM, Campbell SB, Isbel NM, Marlton P, Cobcroft R, Gill D, Cull G: Neutrophil dysplasia characterized by a pseudo-Pelger-Hüet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. Pathology 2002;34:263–266.
8.
European Mycophenolate Mofetil Co-Operative Study Group: Mycophenolate mofetil in renal transplantation: 3-year results from placebo-controlled trials. Transplantation 1999;68:391–397.
9.
Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H: A randomized active controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998;66:507–515.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.